News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe

News

Webcast

Webcasts

January 18, 2024

Navigating Success During a Rare Disease Product Launch

Author(s):

Herspiegel

Webinar Date/Time: Thu, Feb 15, 2024 11:00 AM EST

Join us to learn about current trends in rare disease drug development and commercialization, as well as implications for rare disease product launches. In this webcast, we share learnings from our 125+ pharmaceutical product launches, insights to identify risk and strategies to mitigate them, and best practices for launch timelines and stage gates.

Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1651137&tp_key=395bcd3d64

Event Overview:

Rare disease products account for half of all US FDA approvals, most with fast-track designations, which means compressed launch timelines and increasingly competitive markets with smaller patient populations. Organizations need to start their project journey 24-36 months prior to approval to gain a comprehensive understanding of the patient journey, educate providers effectively, foster advocacy, and establish a clear path to diagnosis and access to treatment. Early alignment to a cross-functional strategy supports decisions about prioritizing and judiciously allocating limited resources pre-approval.

If you are developing assets for rare disease indications, take advantage of this presentation to learn how to ensure your launch is set up for success.

Key Learning Objectives:

  • Trends in rare disease drug development and commercialization
  • Unique considerations for major commercial decisions in rare disease markets
  • Identification of challenges and effective strategies to address them
  • Best practices for launch timelines and stage gates for Medical Affairs, Market Access, and Commercial perspectives

Who Should Attend:

  • CEOs, Chief Commercial Officers, Launch Leadership, Marketing Heads, EVPs of Marketing of organizations that are developing therapies for rare disease conditions.

Speakers:

Kapil Raina, MD
Principal, Market Access
Herspiegel

Brian Williams
SVP, Commercial Strategy and Execution
Herspiegel

Chris Zealey, MSc
Principal, Science and Strategy
Sixsense Strategy Group, a Herspiegel Company

Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1651137&tp_key=395bcd3d64

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Advertisement
Acceleration and Ambition
August 28th 2025

Acceleration and Ambition

Mike Hollan
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 28th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
Rethinking Market Access in CEE: Time to Bust the Myths
August 28th 2025

Rethinking Market Access in CEE: Time to Bust the Myths

Christian Schuler Wiktor Miller
Peter Ax, UpScriptHealth
August 28th 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities
August 28th 2025

AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities

Don Tracy, Associate Editor
Bayer Layoffs Reach 12,000 in Ongoing $2.3 Billion Restructuring Plan
August 28th 2025

Bayer Layoffs Reach 12,000 in Ongoing $2.3 Billion Restructuring Plan

Don Tracy, Associate Editor
Related Content
Advertisement
Acceleration and Ambition
August 28th 2025

Acceleration and Ambition

Mike Hollan
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 28th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
Rethinking Market Access in CEE: Time to Bust the Myths
August 28th 2025

Rethinking Market Access in CEE: Time to Bust the Myths

Christian Schuler Wiktor Miller
Peter Ax, UpScriptHealth
August 28th 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities
August 28th 2025

AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities

Don Tracy, Associate Editor
Bayer Layoffs Reach 12,000 in Ongoing $2.3 Billion Restructuring Plan
August 28th 2025

Bayer Layoffs Reach 12,000 in Ongoing $2.3 Billion Restructuring Plan

Don Tracy, Associate Editor
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.